专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004007537A3 MODIFIED ADENOVIRAL FIBER WITH ABLATED TO CELLULAR RECEPTORS 审中-公开
标题翻译：改良的腺病毒纤维与细胞受体结合
公开(公告)号：WO2004007537A3
公开(公告)日：2004-03-11
申请号：PCT/IB0303336
申请日：2003-07-10
申请人： TRANSGENE SA , ROSA-CALATRAVA MANUEL , LEISSNER PHILIPPE , LEGRAND VALERIE
发明人： ROSA-CALATRAVA MANUEL , LEISSNER PHILIPPE , LEGRAND VALERIE
IPC分类号： A61K38/00 , A61K48/00 , C07K14/075 , C12N7/04 , C12N15/86 , C12N15/861
CPC分类号： C12N15/86 , A61K38/00 , A61K48/00 , C07K14/005 , C12N7/00 , C12N2710/10322 , C12N2710/10343 , C12N2710/10345 , C12N2710/10362 , C12N2810/40
摘要： The present invention concerns a modified adenoviral fiber containing at least one mutation affecting one or more amino acid residue(s) of said adenoviral fiber interacting with at least one glycosaminoglycan and/or sialic acid-containing cellular receptor, as well as a trimer of such a modified adenoviral fiber. The present invention also relates to a DNA fragment, an expression vector encoding said modified adenoviral fiber. The present invention also concerns an adenoviral particle lacking a wild-type fiber and comprising the trimer of modified adenoviral fibers as well as a process for producing such an adenoviral particle. Theto present invention also provides a composition comprising such an adenoviral particle and the therapeutic use thereof.
摘要翻译：本发明涉及一种修饰的腺病毒纤维，其包含影响与至少一种糖胺聚糖和/或含唾液酸的细胞受体相互作用的所述腺病毒纤维的一个或多个氨基酸残基的至少一个突变，以及这样的三聚体改良的腺病毒纤维。本发明还涉及DNA片段，编码所述修饰的腺病毒纤维的表达载体。本发明还涉及缺乏野生型纤维并且包含修饰的腺病毒纤维的三聚体的腺病毒颗粒以及产生这种腺病毒颗粒的方法。本发明还提供了包含这种腺病毒颗粒的组合物及其治疗用途。

2. 发明申请

WO2005113781A3 VECTORS FOR USE IN GENE AND CANCER THERAPY 审中-公开
标题翻译：用于基因和癌症治疗的药物
公开(公告)号：WO2005113781A3
公开(公告)日：2006-11-23
申请号：PCT/GB2005002016
申请日：2005-05-23
申请人： GOT A GENE AB , HABIB NAGY , CENTRE NAT RECH SCIENT , BOULANGER PIERRE , LINDHOLM LEIF , MAGNUSSON MARIA , HONG SAW SEE , ROSA-CALATRAVA MANUEL
发明人： BOULANGER PIERRE , LINDHOLM LEIF , MAGNUSSON MARIA , HONG SAW SEE , ROSA-CALATRAVA MANUEL
IPC分类号： C12N15/861 , A61K47/48 , C07K14/075 , C12N15/86
CPC分类号： C07K14/005 , A61K47/64 , A61K2039/5256 , C07K2319/33 , C07K2319/50 , C12N15/86 , C12N2710/10322 , C12N2710/10345 , C12N2810/50
摘要： The present invention relates to a vector comprising a nucleic acid molecule and a peptide or peptide derivative, said peptide or peptide derivative comprising a peptide of general Formula (I) R 1 - R
摘要翻译：本发明涉及包含核酸分子和肽或肽衍生物的载体，所述肽或肽衍生物包含通式（I）的肽R 1 - [R

3. 发明专利

AU2003206815A2 Adenoviral vectors for modulating the cellular activities associated with PODs 未知
公开(公告)号：AU2003206815A2
公开(公告)日：2003-09-02
申请号：AU2003206815
申请日：2003-01-31
申请人： TRANSGENE SA
发明人： ROSA-CALATRAVA MANUEL
IPC分类号： C12N15/09 , A61K35/76 , A61K38/00 , A61K38/16 , A61K48/00 , A61P35/00 , C07K14/075 , C12N5/10 , C12N7/00 , C12N15/861
摘要： The present invention concerns a method of modulating one or more cellular activities dependent on a POD nuclear structure in a host cell through the action of a molecule of adenoviral origin, wherein said molecule of adenoviral origin is capable of interacting with the cellular function of said POD nuclear structure. In a first aspect, the present invention provides a method, a replication-defective adenoviral vector and a composition intended to reduce or inhibit one or more POD-dependent cellular activities by introducing said adenoviral molecule in the host cell. The invention also relates to the use of such replication-defective adenoviral vector or molecule to provide a reduction or an inhibition of the antiviral or apoptosis cellular activities as well as to provide a reduction of the toxicity induced by a replication-defective adenovirus vector or to enhance transgene expression driven from said replication-defective adenovirus vector. In a second aspect, the present invention provides a replication-competent adenoviral vector having native pIX or E4orf3 gene non-functional or deleted, as well as a viral particle, a host cell and a composition comprising such a replication-competent adenoviral vector and a method of treatment using such a replication-competent adenoviral vector. The present invention also concerns a method of enhancing apoptosis in a host cell using such a replication-competent adenoviral vector.

4. 发明专利

FR3089789A1 PRODUCTION DE VACCINS VIRAUX SUR UNE LIGNEE CELLULAIRE AVIAIRE 未知
公开(公告)号：FR3089789A1
公开(公告)日：2020-06-19
申请号：FR1872957
申请日：2018-12-14
申请人： UNIV CLAUDE BERNARD LYON , CENTRE NAT RECH SCIENT , INST NAT SANTE RECH MED , UNIV LAVAL , TRANSGENE SA , ECOLE NORMALE SUPERIEURE LYON
发明人： ROSA-CALATRAVA MANUEL , BOIVIN GUY , DUBOIS JULIA , PIZZORNO MARIO ANDRES , TERRIER OLIVIER , TRAVERSIER AURÉLIEN
IPC分类号： A61K39/12 , A61K39/155 , A61P31/14 , C12N7/01 , C12N7/04
摘要： La présente invention concerne l’utilisation de la lignée cellulaire immortalisée ECACC 09070703, déposée le 7 juillet 2009 auprès de l’European Collection of Cell Cultures (ECACC, Salisbury, Royaume Uni) sous le numéro 09070703, pour la production d’un vaccin viral constitué par une souche atténuée dérivée d’un metapneumovirus humain. Figure pour l’abrégé : NON

5. 发明专利

CA2474777A1 ADENOVIRAL VECTORS FOR MODULATING THE CELLULAR ACTIVITIES ASSOCIATED WITH PODS 未知
公开(公告)号：CA2474777A1
公开(公告)日：2003-08-07
申请号：CA2474777
申请日：2003-01-31
申请人： TRANSGENE SA
发明人： ROSA-CALATRAVA MANUEL
IPC分类号： C12N15/09 , A61K35/76 , A61K38/00 , A61K38/16 , A61K48/00 , A61P35/00 , C07K14/075 , C12N5/10 , C12N7/00 , C12N15/861
摘要： The present invention concerns a method of modulating one or more cellular activities dependent on a POD nuclear structure in a host cell through the action of a molecule of adenoviral origin, wherein said molecule of adenovir al origin is capable of interacting with the cellular function of said POD nuclear structure. In a first aspect, the present invention provides a metho d, a replication-defective adenoviral vector and a composition intended to redu ce or inhibit one or more POD-dependent cellular activities by introducing said adenoviral molecule in the host cell. The invention also relates to the use of such a replication-defective adenoviral vector or molecule to provide a reduction or an inhibition of the antiviral or apoptosis cellular activities as well as to provide a reduction of the toxicity induced by a replication- defective adenovirus vector or to enhance transgene expression driven from said replication~defective adenovirus vector. In a second aspect, the presen t invention provides a replication-competent adenoviral vector having the nati ve pIX or E4orf3 gene non~functional or deleted, as well as a viral particle, a host cell and a composition comprising such a replication-competent adenovir al vector and a method of treatment using such a replication-competent adenovir al vector. The present invention also concerns a method of enhancing apoptosis in a host cell using such a replication-competent adenoviral vector.

6. 发明专利

AU2003247128A1 MODIFIED ADENOVIRAL FIBER ABLATED IN BINDING TO GLYCOSAMINOGLYCAN OR SIALIC ACID-CONTAINING CELLULAR RECEPTORS 未知
公开(公告)号：AU2003247128A1
公开(公告)日：2004-02-02
申请号：AU2003247128
申请日：2003-07-10
申请人： TRANSGENE SA
发明人： LEGRAND VALERIE , ROSA-CALATRAVA MANUEL , LEISSNER PHILIPPE
IPC分类号： A61K38/00 , A61K48/00 , C07K14/075 , C12N7/04 , C12N15/86 , C12N15/861 , C07K14/07
摘要： The present invention concerns a modified adenoviral fiber containing at least one mutation affecting one or more amino acid residue(s) of said adenoviral fiber interacting with at least one glycosaminoglycan and/or sialic acid-containing cellular receptor, as well as a trimer of such a modified adenoviral fiber. The present invention also relates to a DNA fragment, an expression vector encoding said modified adenoviral fiber. The present invention also concerns an adenoviral particle lacking a wild-type fiber and comprising the trimer of modified adenoviral fibers as well as a process for producing such an adenoviral particle. Theto present invention also provides a composition comprising such an adenoviral particle and the therapeutic use thereof.

7. 发明专利

FR3089789B1 PRODUCTION DE VACCINS VIRAUX SUR UNE LIGNEE CELLULAIRE AVIAIRE 未知
公开(公告)号：FR3089789B1
公开(公告)日：2022-05-27
申请号：FR1872957
申请日：2018-12-14
申请人： UNIV CLAUDE BERNARD LYON , CENTRE NAT RECH SCIENT , INST NAT SANTE RECH MED , UNIV LAVAL , TRANSGENE SA , ECOLE NORMALE SUPERIEURE LYON
发明人： ROSA-CALATRAVA MANUEL , BOIVIN GUY , DUBOIS JULIA , PIZZORNO MARIO ANDRES , TERRIER OLIVIER , TRAVERSIER AURÉLIEN
IPC分类号： A61K39/12 , A61K39/155 , A61P31/14 , C12N7/01 , C12N7/04
摘要： La présente invention concerne l’utilisation de la lignée cellulaire immortalisée ECACC 09070703, déposée le 7 juillet 2009 auprès de l’European Collection of Cell Cultures (ECACC, Salisbury, Royaume Uni) sous le numéro 09070703, pour la production d’un vaccin viral constitué par une souche atténuée dérivée d’un metapneumovirus humain. Figure pour l’abrégé : NON

8. 发明专利

CA2491805A1 MODIFIED ADENOVIRAL FIBER WITH ABLATED TO CELLULAR RECEPTORS 未知
公开(公告)号：CA2491805A1
公开(公告)日：2004-01-22
申请号：CA2491805
申请日：2003-07-10
申请人： TRANSGENE SA
发明人： LEISSNER PHILIPPE , ROSA-CALATRAVA MANUEL , LEGRAND VALERIE
IPC分类号： A61K38/00 , A61K48/00 , C07K14/075 , C12N7/04 , C12N15/86 , C12N15/861
摘要： The present invention concerns a modified adenoviral fiber containing at lea st one mutation affecting one or more amino acid residue(s) of said adenoviral fiber interacting with at least one glycosaminoglycan and/or sialic acid- containing cellular receptor, as well as a trimer of such a modified adenoviral fiber. The present invention also relates to a DNA fragment, an expression vector encoding said modified adenoviral fiber. The present invention also concerns an adenoviral particle lacking a wild-type fiber and comprising the trimer of modified adenoviral fibers as well as a process for producing such an adenoviral particle. Theto present invention also provides a composition comprising such an adenoviral particle and the therapeutic use thereof.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式